Prediction of Alzheimer disease in subjects with amnestic and nonamnestic MCI
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To compare the predictive accuracy of β-amyloid (Aβ)1-42 and total tau in CSF, hippocampal volume (HCV), and APOE genotype for Alzheimer disease (AD)-type dementia in subjects with amnestic mild cognitive impairment (aMCI) and nonamnestic mild cognitive impairment (naMCI). METHODS: We selected 399 subjects with aMCI and 226 subjects with naMCI from a multicenter memory clinic-based cohort. We measured CSF Aβ1-42 and tau by ELISA (n = 231), HCV on MRI (n = 388), and APOE ε4 (n = 523). Follow-up was performed annually up to 5 years. Outcome measures were progression to AD-type dementia and cognitive decline. RESULTS: At least 1 follow-up was available for 538 subjects (86%). One hundred thirty-two subjects with aMCI (38%) and 39 subjects with naMCI (20%) progressed to AD-type dementia after an average follow-up of 2.5 years. CSF Aβ1-42, tau, Aβ1-42/tau ratio, HCV, and APOE ε4 predicted AD-type dementia in each MCI subgroup with the same overall diagnostic accuracy. However, CSF Aβ1-42 concentration was higher and hippocampal atrophy less severe in subjects with naMCI compared with aMCI. This reduced the sensitivity but increased the specificity of these markers for AD-type dementia in subjects with naMCI. CONCLUSIONS: AD biomarkers are useful to predict AD-type dementia in subjects with aMCI and naMCI. However, biomarkers might not be as sensitive for early diagnosis of AD in naMCI compared with aMCI. This may have implications for clinical implementation of the National Institute on Aging and Alzheimer's Association criteria.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Albert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.008 · Cited by 10,152
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects
Shaw, L. M., Vanderstichele, H., Knapik‐Czajka, M., Clark, C. M., Aisen, P. S., Petersen, R. C., Blennow, K., Soares, H., Simon, A., Lewczuk, P., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21610 · Cited by 2,065
Self-citationPathologic correlates of incidental MRI white matter signal hyperintensities
Fazekas, F., Kleinert, R., Offenbacher, H., Schmidt, R., Kleinert, G., Payer, F., Radner, H., & Lechner, H. (1993) · Neurology · doi:10.1212/wnl.43.9.1683 · Cited by 1,619
The neuropathology of probable Alzheimer disease and mild cognitive impairment
Schneider, J. A., Arvanitakis, Z., Leurgans, S. E., & Bennett, D. A. (2009) · Annals of Neurology · doi:10.1002/ana.21706 · Cited by 935
Blennow, K., Wallin, A., Ågren, H., Spenger, C., Siegfried, J., & Vanmechelen, E. (1995) · Molecular and Chemical Neuropathology · doi:10.1007/bf02815140 · Cited by 789
Self-citationImproved discrimination of AD patients using β-amyloid (1-42) and tau levels in CSF
Hulstaert, F., Blennow, K., Ivanoiu, A., Schoonderwaldt, H. C., Riemenschneider, M., Deyn, P. P. D., Bancher, C., Cras, P., Wiltfang, J., Mehta, P. D., et al. (1999) · Neurology · doi:10.1212/wnl.52.8.1555 · Cited by 724
Self-citationAndreasen, N., Hesse, C., Davidsson, P., Minthon, L., Wallin, A., Winblad, B., Vanderstichele, H., Vanmechelen, E., & Blennow, K. (1999) · Archives of Neurology · doi:10.1001/archneur.56.6.673 · Cited by 660
Self-citationComparing predictors of conversion and decline in mild cognitive impairment
Landau, S. M., Harvey, D., Madison, C. M., Reiman, E. M., Foster, N. L., Aisen, P. S., Petersen, R. C., Shaw, L. M., Trojanowski, J. Q., Jack, C. R., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181e8e8b8 · Cited by 616
Visser, P. J., Verhey, F., Knol, D. L., Scheltens, P., Wahlund, L.-O., Freund-Levi, Y., Tsolaki, M., Minthon, L., Wallin, Å. K., Hampel, H., et al. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70139-5 · Cited by 614
Self-citationInjury markers predict time to dementia in subjects with MCI and amyloid pathology
van Rossum, I. A., Vos, S. J. B., Burns, L., Knol, D. L., Scheltens, P., Soininen, H., Wahlund, L.-O., Hampel, H., Tsolaki, M., Minthon, L., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e3182704056 · Cited by 136
Self-citation
Cited by
Prevalence and prognosis of Alzheimer’s disease at the mild cognitive impairment stage
Vos, S. J. B., Verhey, F., Frölich, L., Kornhuber, J., Wiltfang, J., Maier, W., Peters, O., Rüther, E., Nobili, F., Morbelli, S., et al. (2015) · Brain · doi:10.1093/brain/awv029 · Cited by 383
Self-citationAmyloid-β and tau complexity — towards improved biomarkers and targeted therapies
Polanco, J. C., Li, C., Bodea, L.-G., Martinez-Marmol, R., Meunier, F. A., & Götz, J. (2018) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.162 · Cited by 378
Proteome profiling in cerebrospinal fluid reveals novel biomarkers of Alzheimer's disease
Bader, J. M., Geyer, P. E., Müller, J. B., Strauss, M. T., Koch, M., Leypoldt, F., Koertvelyessy, P., Bittner, D., Schipke, C. G., Incesoy, E. I., et al. (2020) · Molecular Systems Biology · doi:10.15252/msb.20199356 · Cited by 286
Tau-based therapies in neurodegeneration: opportunities and challenges
Li, C., & Götz, J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.155 · Cited by 272
Shaw, L. M., Arias, J., Blennow, K., Galasko, D., Molinuevo, J. L., Salloway, S., Schindler, S., Carrillo, M. C., Hendrix, J. A., Ross, A., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.07.220 · Cited by 266
“[110] Vos SJ, van Rossum IA, Verhey F, Knol DL, Soininen H, Wahlund LO, et al.”
BackgroundSelf-citation
Metadata
- Authors
- Vos, S. J. B., van Rossum, I. A., Verhey, F., Knol, D. L., Soininen, H., Wahlund, L.-O., Hampel, H., Tsolaki, M., Minthon, L., Frisoni, G. B., Froelich, L., Nobili, F., van der Flier, W., Blennow, K., Wolz, R., Scheltens, P., & Visser, P. J.
- Venue
- Neurology
- Published
- 2013-03-19
- Volume
- 80
- Issue
- 12
- Pages
- 1124-1132
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2064126078
- Cited by
- 133
- References
- 10
- FWCI
- 10.85
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prediction of Alzheimer disease in subjects with amnestic and nonamnestic MCI. https://app.cochat.ai/papers/10.1212/wnl.0b013e318288690c
- The paper
- Vos, S. J. B., van Rossum, I. A., Verhey, F., Knol, D. L., Soininen, H., Wahlund, L.-O., Hampel, H., Tsolaki, M., Minthon, L., Frisoni, G. B., Froelich, L., Nobili, F., van der Flier, W., Blennow, K., Wolz, R., Scheltens, P., & Visser, P. J. (2013). Prediction of Alzheimer disease in subjects with amnestic and nonamnestic MCI. Neurology. https://doi.org/10.1212/wnl.0b013e318288690c
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.